Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2024—Horiba announced that it has expanded its compact hematology instrument range with the launch of three models now with erythrocyte sedimentation rate onboard. The Yumizen H550E (autoloader), H500E CT (closed tube), and H500E OT (open tube) offer combined testing for CBC with differential and ESR results from whole blood in 60 seconds.
August 2024—Diasorin announced it has received 510(k) clearance from the FDA for the company’s Liaison Plex Yeast Blood Culture assay, the second molecular multiplexing panel on the Liaison Plex. The assay, which is driven by Gram stain, detects 16 pathogens commonly associated with fungemia. The Liaison Plex sample-to-answer system uses room-temperature consumables, has a hands-on time of two minutes, and produces results in less than two hours.
August 2024—TechLab, a part of SSI Diagnostica Group, announced that its C. Diff Quik Chek Complete test has received certification under European in vitro diagnostic medical device regulation. The test is a rapid membrane enzyme immunoassay designed for the simultaneous detection of Clostridioides difficile glutamate dehydrogenase antigen and toxins A and B in a single reaction well and provides GDH and toxin results within about 30 minutes.
August 2024—Clarapath, a medical robotics company headquartered in Hawthorne, NY, announced it has entered into a strategic collaboration with Mayo Clinic to advance laboratory automation. Clarapath’s SectionStar is an all-in-one tissue sectioning and transfer system that is designed to increase capacity, reliability, and consistency while minimizing the need for highly skilled labor. The collaboration combines Clarapath’s tissue solution and domain experts with the clinical insights and expertise of the Mayo Clinic to enable laboratories to digitally transform the quality, safety, cost, and throughput of their histology process.
August 2024—Quest Diagnostics launched a blood biomarker test for phosphorylated tau 217, a biomarker associated with Alzheimer’s disease. It is the latest addition to Quest’s AD-Detect portfolio of tests, which also includes tests for p-tau181, amyloid beta proteins, and apolipoprotein E isoforms.
August 2024—Verichem Laboratories is now offering a multilevel, multianalyte, and ready-to-use Enzyme ER Calibration Verifier kit designed for the calibration verification of enzyme assays on wet chemistry testing systems. The enzyme components within the materials include amylase, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, cholinesterase, creatine phosphokinase, gamma-glutamyltransferase, lactate dehydrogenase, and lipase and are intended to be treated as patient specimens. The materials have a shelf life and open-vial stability of 18 months.
August 2024—Bruker Corp. announced the launch of mass spectrometry systems at the American Society for Mass Spectrometry 72nd annual conference on mass spectrometry and allied topics, June 2–6, in Anaheim, Calif.
August 2024—Roche has launched the Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail assay in countries accepting the CE mark. The assay is intended for the qualitative detection of kappa and lambda mRNA in formalin-fixed, paraffin-embedded human bone marrow and lymphoid tissue stained on a BenchMark IHC/ISH instrument using chromogenic in situ hybridization and visualized using light microscopy. The test is intended as an aid in the identification of B-cell lymphomas and plasma cell neoplasms. The results of the assay should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls. The product is intended for in vitro diagnostic use.
August 2024—MedTech Breakthrough announced that Epredia has been selected as the winner of best new technology solution—pathology for its SlideMate Laser printer in the 8th annual MedTech Breakthrough Awards program. The SlideMate Laser is designed for clinical laboratories and provides high-resolution, 600-dpi laser printing on microscope slides, enabling laboratories to include more identifying information directly on the tab of the slides. The technology can embed up to 50 characters in a barcode on each slide and offers on-demand and batch printing options. The laser printer’s software can be directly interfaced to a laboratory information system.
August 2024—BioMérieux announced that its Vitek Reveal AST system has received FDA 510(k) clearance. The modular system can deliver actionable results for Gram-negative bacteria directly from positive blood cultures in an average of 5.5 to 6 hours, enabling same-day treatment decision-making for patients suffering from bacteremic sepsis. The system is also CE marked under the in vitro diagnostic medical devices directive and in vitro diagnostic medical devices regulation in Europe.
